Non-Small Cell Lung Cancer (NSCLC) is the most common & epithelial type of lung cancer that occurs in different forms, viz., Squamous Cell Carcinoma (SCC), Large Cell Carcinoma (LCC), & Adenocarcinoma. Smoking is mainly responsible for NSCLC since smokers are more likely to develop NSCLC. However, it is observed that adenocarcinoma has also occurred in patients with no smoking history.
Further, as the prevalence of lung cancers is rising worldwide, the demand for their diagnosis & treatments is also surging rapidly, which, in turn, is compelling governments & leading biopharma companies to boost drug developments & distributions in order to cater to the unmet patient needs for efficient & safe NSCLC treatments.
The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during the forecast period, i.e., 2022-27. Most of the market growth would be driven by the growing number of patients with Non-Small Cell Lung Cancer (NSCLC) type of lung cancer and the mounting demand for its effective diagnosis & treatment worldwide.
Observing the growing influx of NSCLC patients globally, governments of different countries are investing massively in the healthcare sector to strengthen the oncology department, including the NSCLC, and encourage the leading biopharmaceutical companies to discover novel therapeutics with enhanced efficacy & safety. As a result, the expansion of various players and the emergence of local companies are seen extensively worldwide.
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Regions Covered||North America: The US, Canada, Mexico|
|South America: Brazil, Rest of South America|
|Europe: Germany, The UK, France, Spain, Italy, Rest of Europe|
|Asia-Pacific: China, Japan, India, South Korea, Rest of Asia Pacific|
|Middle East & Africa: GCC, South Africa, Rest of Middle East and Africa|
|Key Companies Profiled||Allergan (AbbVie), AstraZeneca PLC, Boehringer Ingelheim, Bristol Myers Squibb, Eisai Co., Ltd, Eli Lilly and Company, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, Other|
|Unit Denominations||USD Million/Billion|
Additionally, growing awareness among people about the availability of diagnosis & various treatments for NSCLC through government engagement in campaigns, advertisements, etc., i.e., portraying a rising patient pool across different countries, is further augmenting the overall market growth.
The leading biotechnology & pharmaceutical companies like Pfizer Inc. are developing & introducing sophisticated targeted therapies like Vizimpra & Lorbrena for NSCLC patients, i.e., another crucial aspect projecting remunerative prospects for the Global Non-Small Cell Lung Cancer (NSCLC) Market through 2027.
Based on the Cancer Type:
Of all cancer types, adenocarcinoma is anticipated to dominate the Global Non-Small Cell Lung Cancer (NSCLC) Market with the largest share during 2022-27. It attributes principally to higher cases of adenocarcinoma than other types of NSCLC, i.e., propagating the need for its effective diagnosis & treatment.
Adenocarcinoma generally occurs in the outer region of the lungs, grows slower than other lung cancers, and is more likely to be diagnosed in its early stage. It is seen commonly in females & non-smoker males. Apart from this, the younger generation is among the prominent patients.
Governments of different countries are making active efforts to spread awareness of the availability of diagnosis & treatment and the need to restrain habits like smoking. With rapid developments in medical science, there are various treatments for NSCLC, depending upon the patient's health condition:
Based on the Treatment:
Of them all, immunotherapy is likely to contribute significantly to the overall market expansion through 2027. It owes principally to the growing awareness among people about its benefits like better efficacy & safety. Immunotherapy drugs strengthen & direct the immune system of the patient to identify & kill the cancer cells effectively. Immune checkpoint inhibitors are the major category of immunotherapy drugs used extensively in NSCLC treatment, which turns the immune system on for targeting the cancer cells directly & attacking potentially harmful agents in the body.
If the immune response begins to affect healthy tissues, turning off checkpoint inhibitors can prevent the damage. Programmed Cell Death Protein 1/Ligand 1 (PD-1/PD-L1) & Cytotoxic T Lymphocyte-Associated Antigen (CTLA-4) are a few commonly used immune checkpoint inhibitors.
The application of immunotherapy, combined with other treatments like surgery, chemotherapy, & radiation therapy, among others, is demonstrating positive outcomes in NSCLC patients worldwide and is an emerging trend globally. Nonetheless, with the escalating prevalence of NSCLC, the availability of treatments like immunotherapy in multiple options is becoming easy and playing a prominent role in driving the global market.
Geographically, the Global Non-Small Cell Lung Cancer (NSCLC) Market expands across:
Of all regions globally, North America acquired the largest share in the Non-Small Cell Lung Cancer (NSCLC) Market in previous years, and the same trend is likely during 2022-27. It owes principally to the high rate of patients with lung cancer, especially NSCLC, i.e., a prominent cause of death across different countries in the region. It, in turn, is instigating governments to invest substantially in developing new medications & bring innovations to the existing ones to cater to the high unmet needs of patients for treatments & offer them positive outcomes.
Besides, the increasing population of smokers and high exposure to toxins like asbestos and elements of air pollution are the other aspects causing NSCLC among people across North America, i.e., leading to increasing rates of diagnosis & therapeutics and, in turn, stimulating the regional market growth.
On the other hand, Asia-Pacific is anticipated to demonstrate the fastest market growth in the coming years, principally due to the mounting focus of governments of different countries in the region on developing the robust healthcare infrastructure, especially oncology, including NSCLC cancer.
In Asia-Pacific, countries like India & China project lucrative opportunities for the leading players due to massive healthcare expenditure & favorable policies for the development & clinical trials of NSCLC therapeutics. It, in turn, would showcase the active participation of the leading biopharma companies in contributing to the fastest growth of the Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market through 2027.
Key Questions Answered in the Market Research Report:
Frequently Asked Questions
A. The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during 2022-27.
A. The growing incidence of NSCLC patients and increasing funding by governments on R&D of novel drugs for NSLC treatment are the prominent factors projected to drive the Global Non-Small Cell Lung Cancer (NSCLC) Market through 2027.
A. The mounting adoption of a combination of therapies like surgery, immunotherapy, radiation, etc., is the key trend in the Global Non-Small Cell Lung Cancer (NSCLC) Market.
A. Combination therapies are anticipated to emerge as an area of remunerative opportunities for the leading players in the Global Non-Small Cell Lung Cancer (NSCLC) Market over the forecast years.
A. Globally, North America is projected to acquire a prominent share in the Non-Small Cell Lung Cancer (NSCLC) Market through 2027.